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Damaging coding variants 
within kainate receptor channel 
genes are enriched in individuals 
with schizophrenia, autism and 
intellectual disabilities
Maria Koromina, Miles flitton, Alix Blockley, ian R. Mellor & Helen M. Knight*
Schizophrenia (Scz), autism spectrum disorder (ASD) and intellectual disability are common complex 
neurodevelopmental disorders. Kainate receptors (KARs) are ionotropic glutamate ion channels 
involved in synaptic plasticity which are modulated by auxiliary NETO proteins. Using UK10K 
exome sequencing data, we interrogated the coding regions of KAR and neto genes in individuals 
with Scz, ASD or intellectual disability and population controls; performed follow-up genetic 
replication studies; and, conducted in silico and in vitro functional studies. We found an excess of 
Loss-of-function and missense variants in individuals with Scz compared with control individuals 
(p = 1.8 × 10−10), and identified a significant burden of functional variants for Scz (p < 1.6 × 10−11) and 
ASD (p = 6.9 × 10−18). Single allele associations for 6 damaging missense variants were significantly 
replicated (p < 5.0 × 10−15) and confirmed GRIK3 S310A as a protective genetic factor. Functional 
studies demonstrated that three missense variants located within GluK2 and GluK4, GluK2 (K525E) and 
GluK4 (Y555N, L825W), affect agonist sensitivity and current decay rates. These findings establish that 
genetic variation in KAR receptor ion channels confers risk for schizophrenia, autism and intellectual 
disability and provide new genetic and pharmacogenetic biomarkers for neurodevelopmental disease.
Schizophrenia and autism are common, highly heritable debilitating neurodevelopmental disorders which are 
often comorbid with intellectual disability. Advances in genomic technology suggest a role for both common and 
rare variants contributing to genetic risk1–4. For instance, whole genome and exome sequencing studies have indi-
cated that ultra-rare Loss-of-Function (LoF) point mutations and indel and CNV variants that truncate proteins, 
are enriched in individuals with neuropsychiatric disease and are both inherited and de novo5–9. Such studies 
commonly find that the disrupted genes are involved in synaptic function, which has led to the increasingly used 
term ‘synaptopathy’ for brain disorders that are thought to arise from synaptic dysfunction10–12.
Kainate receptors (KARs) are ionotropic glutamatergic receptors which form functional ion channels by 
tetrameric combinations of five different subunits. GluK1-3 subunits form functional homomeric or hetero-
meric receptors while GluK4 and GluK5 participate as functional receptors when combined with GluK1-3 sub-
units. Each subunit consists of an extracellular amino terminal domain, an extracellular ligand binding domain, 
three transmembrane domains and a loop M2, and a C-terminal domain. Mutating amino acids in these con-
served regions gives rise to changes in channel properties13 and can alter the affinity for external cations such as 
sodium and lithium14,15. KAR channel properties are also regulated by the presence of the KAR auxiliary subunits 
Neuropilin And Tolloid Like 1, NETO1, and Neuropilin And Tolloid Like 2, NETO216–18.
KARs contribute to generating post-synaptic excitatory responses and to shorter term synaptic plasticity 
mechanisms by influencing presynaptic transmitter release19. In recent years, their action in non-canonical G pro-
tein coupled signalling, new forms of Long Term Potentiation, and synaptic targeting mechanisms have also been 
recognised20–23. NETO1 and NETO2 are single pass transmembrane CUB domain-containing proteins which 
influence the trafficking of KAR subunits and kinetics of KAR function24. During development KARs and Netos 
are highly expressed in the brain and are important for synaptogenesis, neurite outgrowth and glutamatergic 
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pathway connectivity25–27. Rodent knock out and transgenic models have provided some evidence that loss of 
these receptors influences brain function and behaviour in a manner analogous to human disease28–33. In humans, 
common, non-coding, intronic variants and private de novo mutations located within specific GluK subunit genes 
(e.g. GRIK1, GRIK2, GRIK3, GRIK4, GRIK5) have been associated with a broad spectrum of neurological dis-
eases34–39 and GluK genotype-dependent changes in cognition, brain activation and response to antidepressant 
and antipsychotic treatments have been reported40–43. However, as yet no comprehensive screen of coding vari-
ants across all GluK genes or KAR auxiliary proteins have been performed in cohorts with intellectual disability 
and neurodevelopmental conditions.
We hypothesize that damaging coding alleles within KAR subunit and NETO genes contribute to risk for 
developing neurodevelopmental disorders. Here we characterised LoF variants, performed single allele asso-
ciation and burden enrichment analysis of damaging coding variants within KAR subunit and NETO genes, in 
individuals with schizophrenia, psychosis, autism and intellectual disabilities available from the UK10K project 
and ExAC study44. We subsequently examined the functional effect of predicted damaging missense variants 
within GluK2 and GluK2/GluK4 receptors using in silico modelling tools and in vitro electrophysiological assays.
Results
Lof and rare missense variants are increased within individuals with neurodevelopmental 
disorders. The pipeline followed for the genetic analysis is presented in Fig. 1. In a first discovery phase, we 
identified 154 non-synonymous variants which included 4 LoF and 150 missense variants and 143 regulatory 
variants within GRIK1-5 and NETO1-2 genes (Table 1). 265 variants had a MAF < 1% and were classified as rare 
or ultra-rare. We postulated that genes, which in the general population, are characterised as having few LoF and 
missense variants would carry high numbers of LoF and damaging variants in individuals with neurodevelop-
mental disorders as these variants putatively contribute to disease risk. In the ExAC project database, GRIK2, 
GRIK3, GRIK5 and NETO1 are all classified as LoF intolerant genes (LoF pLI > 0.90) indicating that these genes 
Figure 1. Genetic analysis workflow. Data sets investigated are shown in blue, methods and analysis in 
green and findings are colored orange. Discovery phase one analyzed WES and WGS from cohorts with 
neurodevelopmental disorders (including severe neuropsychiatric conditions and ASD, ID and dual Scz-ID) 
and general population control cohorts. The second discovery phase investigated two additional schizophrenia 
cohorts. Details of the cohorts are presented in Supplementary Table S1. Single allele associations and burden 
analysis was performed. Associated alleles were followed up by performing case-control studies using the 
ExAC cohort non psychiatric control and psychiatric case populations. Abbreviations: ASD, autism spectrum 
disorders; ExAC, Exome Aggregation Consortium; FINSCZ, Finnish schizophrenia samples; ID, Intellectual 
Disability; MAF, Minor Allele Frequency; Scz, schizophrenia; SNV, Single-Nucleotide Variant; WES, Whole-
Exome Sequencing; WGS, Whole-Genome Sequencing.
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are extremely intolerant of Loss-of-Function variation and hence few LoF mutations are present in the general 
population. As detailed in Table 1, we identified 4 LoF variants within affected individuals who had either ID or 
ASD or comorbid with Scz (GRIK1 L411X, Scz comorbid with ID; GRIK4 S98X, ID; GRIK5 Q848X, ASD; and 
GRIK5 19:42546908 splice acceptor, variant, ASD), and two of which were within the LoF intolerant gene GRIK5. 
No LoF variants were identified in the control cohort.
ExAC also categorizes GRIK2, GRIK3, GRIK4, GRIK5 and NETO1 as missense intolerant genes (missense 
z > 2.80) again suggesting that fewer missense mutations are present in the general population within these genes 
than expected. Of the 150 missense variants identified in the current study, 75 were considered as protein damag-
ing, 40 as possibly damaging variants and 35 as benign. The number of rare and ultra-rare nonsynonymous vari-
ants within affected individuals was found to be higher than the number of rare nonsynonymous variants found 
within control individuals or shared despite the fact that the control population has twice the number of individ-
uals (affected case frequency 0.58; control frequency 0.26; variants found in both cases and controls frequency 
0.16) (Supplementary Tables S4–S7). As indicated in Fig. 2, the majority of LoF and predicted damaging missense 
variants were identified in individuals with Scz and ASD whilst most of the predicted benign missense variants 
were found either in controls or were shared between cases and controls subjects (Supplementary Table S8). In 
contrast to rare LoF and missense mutations, an equal frequency of common non-synonymous, synonymous 
and regulatory variants was found in both case and control individuals. The most common variants identified 
(MAF > 0.1) were synonymous variants (87.5%) and present in both case and control individuals.
We also found that the effect size of rare LoF and missense variants within LoF intolerant genes (LoF 
pLI > 0.90), was larger than the effect size (0.3 compared to −0.2) of rare LoF and missense variants within genes 
with a low LoF tolerance metric (Fig. 2d). In addition, as shown in Fig. 2 and Supplementary Fig. S1, rare LoF and 
missense variants were indicated to have a larger effect size compared to variants classified as regulatory and the 
effect size of rare regulatory variants did not differ between LoF intolerant and LoF tolerant genes.
Single coding alleles associated with risk or protection against developing disease. Two single 
coding variants were found to be significantly associated with disease (Table 1 and Supplementary Figs. S2, S3). 
Gene cDNA Type MAF cases (Gen ct) Diag
MAF con  
(Gen ct) P value OR (CI) MAF ExAC
FIRST DISCOVERY PHASE
GRIK1 c.1232 T > A (p.Leu411*) Non 3.03 × 10−4 (1 T/A) Scz-ID Inf 5.78 × 10−5
GRIK3 c.928 T > G (p.Ser310Ala) Mis 0.17 (451 T/G, 51 G/G) All 0.25 (846 T/G, 113 G/G) 1.01 × 10
−18 0.59 (0.52–0.66) 0.27
GRIK3 c.1756T > G (p.Phe586Val) Mis 0.003 (9 T/G) ASD 2.84 × 10−7 Inf Novel
GRIK4 c.293 C > A (p.Ser98*) Non 3.03 × 10−4 (1 C/A) ID Inf Novel
GRIK5 c.2542 C > T (p.Gln848*) Non 3.03 × 10−4 (1 C/T) ASD Inf Novel
GRIK5 c.2684 C > G (p.Ala895Gly) Mis 0.005 (9 C/G, 4 G/G) Scz 4.06 × 10−5 44.83 (2.70–765) Novel
GRIK5 c.1270-1 G > T SpA 3.03 × 10−4 (1 G/T) ASD Inf Novel
NETO1 c.-143G > T PSC 3.03 × 10−4 (1 G/T) ASD Inf Novel
SECOND DISCOVERY PHASE
GRIK2 c.1525–10 C > T SpI 0.010 (16 C/T) Scz 4.43 × 10−8 42.26 (2.53–704) Novel
GRIK3 c.2593 A > G (p.Arg865Gly) Mis 0.008 (14 A/G) Scz 6.81 × 10−6 73 (4–1226) 0.005
MAF (ct) Cases MAF (ct) Con ExAC P value OR (CI)
ExAC REPLICATION FOLLOW UP (1)
GRIK1 c.2705 T > C (p.Leu902Ser) Mis 0.031 (101/3,288) 0.08 (68,18/90,756) 4.83 × 10−15 0.399 (0.320–0.476)
GRIK3 c.928 T > G (p.Ser310Ala) Mis 0.168 (553/3,288) 0.29 (25,607/90,756) 6.49 × 10−50 0.513 (0.469–0.564)
GRIK5 c.2684 C > G (p.Ala895Gly) Mis 0.005 (17/3,288) 0.00 (0/90,756) 8.55 × 10−24 Inf
MAF (ct) Psy ExAC MAF (ct) Con ExAC P value OR (CI)
ExAC REPLICATION FOLLOW-UP (2)
GRIK1 c.2705 T > C (p.Leu902Ser) Mis 0.040 (1,155/30,000) 0.075 (6,818/90,756) 1.145 × 10−108 0.49 (0.46–0.53)
GRIK3 c.928 T > G (p.Ser310Ala) Mis 0.245 (7,364/30,000) 0.29 (25,607/90,756) 4.076 × 10−35 0.81 (0.80–0.84)
GRIK4 c.1582 G > A (p.Val528Ile) Mis 0.0002 (5/30,000) 0.011 (1,028/90,756) 5.467 × 10−74 0.01 (0.004–0.03)
NETO1 c.1460 C > G (p.Ala487Gly) Mis 6.60 × 10−5 (2/30,000) 0.008 (704/90,756) 7.967 × 10−52 0.009 (0.001–0.03)
NETO2 c.1366 T > A (p.Ser456Thr) Mis 6.60 × 10−5 (2/30,000) 0.009 (808/90,756) 2.056 × 10−59 0.007 (0.001–0.02)
Table 1. LoF and damaging missense variants identified in the discovery and replication phases as significantly 
associated with disease risk. Variant location, type of variant, MAF and allele counts for affected cases, controls 
and population controls (ExAC cohort), diseases diagnosis, p-values for association and Odds Ratios are 
presented. Abbreviations: ASD, Autism spectrum disorder; ExAC, Exome Aggregation Consortium; ct, (allele) 
count; Diag, diagnosis; Gen ct, genotype count; ID, intellectual disability; Inf, infinity; MAF, Minor Allele 
Frequency; Mis, missense variant; Non, nonsense mutation; OR, Odds Ratio; PSC, premature start codon gain; 
Scz, schizophrenia; Scz-ID, dual diagnosis of schizophrenia and ID; SpA, splice acceptor variant; SpI, splice 
intronic variant.
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Figure 2. Frequency and effect size of functional variants and the location of non-synonymous variants within 
GRIK2 and GRIK4. (A) Individuals with severe neuropsychiatric disease (i.e. conditions with psychosis) and 
ASD have a higher percentage of rare functional variants compared to control individuals in the first discovery 
study. (B) Individuals with schizophrenia have a have a higher percentage of rare functional variants compared 
to control individuals in the second discovery study. (C) LoF and missense variants have a larger risk effect 
size than regulatory variants in genes which are classified as LoF and missense intolerant. (D) Risk effect sizes 
are smaller for regulatory variants and benign missense variants compared to LoF and damaging missense 
variants. (E) The location of LoF and damaging missense variants identified within GRIK2 and GRIK4 proteins 
in affected and control individuals. Protein domains are colour coded with the ATD as blue; LBDs (S1 and S2) 
as black; transmembrane domains M1-M3-M4 red; M2 loop as red and the C-terminal domain (CTD), green. 
Damaging missense variants carried in cases or controls or are colour coded as blue and black respectively. 
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GRIK3 S310A, located in the amino terminal domain (ATD), was found to be protective against a broader neu-
rodevelopmental phenotype, e.g. conditions with psychosis and ASD/ID phenotypes (p = 1.01 × 10−18; OR = 0.59, 
CI 0.52–0.66,). GRIK3 F586V, was associated with risk of developing ASD (p = 2.84 × 10−7; OR = Inf). In addi-
tion, A895G located within the cytoplasmic protein domain of GRIK5, was found protective at a nominal level of 
significance against developing schizophrenia (p = 4.06 × 10−5; OR = 44.83, CI 2.70–765).
enrichment of coding variants within GRIK and NETO genes. We analysed the burden and accu-
mulation rates of functional variants and found a significantly increased burden of LoF, missense and regula-
tory variants which included all allelic frequencies in the case population (p = 3.38 × 10−20). Similarly, and as 
detailed in Table 2, we also found an increased burden of ultra-rare and rare LoF, missense and regulatory var-
iants (p = 2.07 × 10−15). When comparing a broader neurodevelopmental phenotype, e.g. ASD, psychosis and 
ID, or a narrower psychosis phenotype with control individuals, we observed a significantly increased burden 
of LoF and missense variants within all GRIK and NETO genes (broad neurodevelopmental, all allele frequen-
cies, p = 2.97 × 10−10; broad neurodevelopmental, ultra-rare and rare p = 6.02 × 10−7; psychosis, all frequencies; 
p = 6.17 × 10−7; psychosis, ultra-rare and rare p = 1.83 × 10−7). We also found a significantly increased burden of 
LoF, missense and regulatory variants at all allele frequencies (p = 6.86 × 10−18) and for ultra-rare and rare vari-
ants alone (p = 1.30 × 10−9) for the combined intellectual disability/ASD cohorts. However, although we found a 
significant burden of common and rare variants (p = 3.15 × 10−11) for ASD/ID, ultra-rare and rare variants alone 
did not reach genome-wide level of significance (p = 0.026).
Burden analysis was also performed for each individual gene (Supplementary Tables S9–S11). GRIK3, GRIK5 
and NETO1, three genes classified as LoF and missense intolerant, were indicated as having an increased burden 
of functional variants (common and rare variants combined for GRIK3 p = 1.26 × 10−5; NETO1 p = 4.66 × 10−16; 
and rare variants only for GRIK5 p = 9.99 × 10−6). We also assessed variant load per gene level grouped by 
either severe neuropsychiatric phenotypes, i.e. conditions with psychosis, or ASD/ID phenotypes. For the 
psychosis grouping, we observed a genome-wide significant burden of rare LoF and missense variants within 
GRIK5 (p = 7.83 × 10−10) and an increased burden of common and rare functional variants within NETO1 
(p = 6.76 × 10−6). For ASD and ID samples, we identified a genome-wide or nominal significant burden of com-
mon and rare LoF, missense and regulatory variants within GRIK3 (p = 3.31 × 10−13), GRIK1 (p = 1.20 × 10−5) 
and NETO1 (p = 2.79 × 10−12).
GRIK and NETO genetic associations in two additional schizophrenia cohorts. In a second dis-
covery phase, we investigated the exomes of two additional schizophrenia datasets, the UKSCZ (N = 553) and 
FSZNK (N = 285) cohorts. Unlike in the first discovery phase where LoF variants were identified in individuals 
with ID or ASD, we did not identify any LoF variants in this second phase. This may relate to the fact that all 
affected individuals had a diagnosis of Scz and not ID or ASD. However, we detected 197 coding variants of 
which 97 were missense variants. 58 missense variants were predicted damaging and 34 (59%) of these damaging 
missense variants were identified within affected individuals only (Supplementary Tables S12–S16). As before, we 
investigated GRIK and NETO single coding alleles for association with risk or protection against Scz (Figs. S1–S3). 
A splice variant within GRIK2 6:102337505, c.1525–10 C > T (p = 4.43 × 10−8; OR = 42.26, CI 2.53–704) and a 
missense variant within GRIK3, R865G, (p = 6.8 × 10−6; OR = 73, CI 4–1226) showed a significant nominal asso-
ciation with risk for schizophrenia (Table 1).
Consistent with our previous findings for a psychosis phenotype, we observed that GRIK and NETO genes had 
high accumulation rates of functional coding variants (Table 2, Supplementary Table S17). For instance, we found 
a significantly increased burden of missense and regulatory variants at all allele frequencies (p = 1.26 × 10−25), and 
a significantly increased burden of just missense variants (p = 4.39 × 10−15). In addition, a higher burden of com-
mon and rare missense variants were found within GRIK3 (p = 5.24 × 10−10) and both NETO1 and NETO2 genes 
had higher accumulation rates of common and rare regulatory variants (p = 1.60 × 10−28 and p = 8.03 × 10−10). 
We also observed a burden of rare regulatory variants within GRIK5 (p = 3.37 × 10−5).
evidence for the robustness of allele associations. To assess the robustness of significantly associ-
ated single alleles identified in discovery phases, we compared allelic frequencies of rare and common coding 
or splicing variants in the UK10K discovery phase affected cases with non-affected exomes from ExAC cohorts 
(N = 45,376). We identified 8 genome-wide significant associations (3 missense, 4 synonymous and 1 splice site) 
listed in Table 1 and Supplementary Table S18 validating our previous findings. Of the 3 missense variants, two 
had significant associations for protection against neuropsychiatric disease, GRIK3 S310A (p = 6.49 × 10−50; 
OR = 0.51, CI 0.47–0.56) and GRIK1 L902S (p = 4.83 × 10−15; OR = 0.40, CI 0.32–0.48), whilst one showed a 
significant association for risk for neuropsychiatric disease, GRIK5 A895G (p = 8.55 × 10−24; OR = Inf). We also 
identified 6 variants associated at the nominal level of significance (3 missense, 1 synonymous and 2 splice site 
variants), Supplementary Table S18.
Finally, using data from ExAC for well individuals (N = 45,376) and from the psychiatric disease arm of the 
ExAC study (N = 15,328) which includes individuals with additional neurological and psychiatric conditions, 
e.g. Tourette’s syndrome, and hence relates to a yet broader neurodevelopmental phenotype, we compared allele 
frequencies for all damaging coding variants which we had previously identified in the earlier phases of the study. 
(F) The location of three damaging missense variants, GluK2 K525E, GluK4 Y555N, and GluK4 L825W. The 
term ‘shared’ denotes variants found within both case and control groups. Abbreviations: ATD, amino terminal 
domain; LoF pLI, propability for LoF intolerance score.
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We observed nine significant associations (p < 2 × 10−34); 5 missense variants, 3 synonymous and one splice var-
iant, details of which are provided in Table 1 and Supplementary Table S19. The levels of significance (1 × 10−6 
to 1 × 10−108) reflects the power to detect associations with very large sample numbers, e.g. N = 45,000, and is 
consistent with values reported for individual variants studied in large cohorts44–46.
Consistent with our previous findings, we again observed a significant difference in allele frequencies for 
the GRIK3 S310A variant (non-affected individuals MAF 0.29, disease MAF 0.25; p = 4.07 × 10−35; OR 0.81, 
CI = 0.80–0.84) and nominal significance for GRIK3 R865G variant (non-affected individuals MAF 0.004, dis-
ease MAF 0.006; p = 2.07 × 10−5; OR 1.49, CI = 1.22–1.73).
In silico and in vitro assays of rare variants within GluK2 and GluK4 TMD and LBD domains 
support a functional effect. Three predicted damaging missense mutations identified in individuals with 
schizophrenia and located within ‘key’ ligand binding (GluK2 K525E) and transmembrane (GluK4 L825W; 
GluK4 Y555N) domains of GluK2 and GluK4 subunits, were examined using in silico modelling tools. We 
found that GluK4 Y555N disrupted a hydrogen bond and resulted in a significant destabilizing thermodynamic 
effect (∆∆G = 1.65). GluK4 L825W did not affect the formation of hydrogen bonds but did however, have a 
slightly destabilizing effect on the total energy (∆∆G = 0.755). The GluK2 LBD K525E mutation led to creation 
of a hydrogen bond but no predicted observable thermodynamic effect was predicted (∆∆G = 0.06), shown in 
Supplementary Figure S4. However, a decrease in predicted positive electrostatic potential was observed over the 
ligand binding domain area of the GluK2 K525E variant (Supplementary Figure S5) and which could influence 
cell surface expression47. Taken together, in silico protein modeling analysis suggests that these three predicted 
damaging mutations could affect protein conformation, structural relationships or electrostatic potential.
To further study functional changes, we expressed wild-type and mutated GluK2 homomers and GluK2/
GluK4 heteromers in Xenopus oocytes and measured their current responses to application of glutamate using 
a voltage-clamp. Currents rose to a peak then decayed to a steady state (Fig. 3b). Because of the temporal limi-
tations of this system, currents represent a mixture of activation, desensitization and deactivation processes but 
presumably with activation dominating the rising phase and desensitization and deactivation dominating the 
decaying phase. We measured the agonist sensitivity of the peak current (EC50) and the current decay rates (τdecay) 
and although these current kinetics are not physiological, we compared changes in responses between wild-type 
and mutant receptors (Fig. 3; Supplementary Table 20).
Variant Type Frequency Disease status P value (SKAT- O)
FIRST DISCOVERY STUDY (1648)
All functional
All (0.0–0.50)
All neurodevelopmental 3.38 × 10−20
Psychosis 1.63 × 10−11
ASD & ID 6.86 × 10−18
Utra rare & rare (<0.01)
All neurodevelopmental 2.07 x 10−15
Psychosis 3.69 × 10−13
ASD & ID 1.30 × 10−9
LoF and missense
All (0.0-0.50)
All neurodevelopmental 2.97 × 10−8
Psychosis 6.17 × 10−7
ASD & ID 3.15 × 10−11
Ultra rare & rare (<0.01)
All neurodevelopmental 6.02 x 10−7
Psychosis 1.83 × 10−10
ASD & ID 0.026
Regulatory
All (0.0–0.50)
All neurodevelopmental 3.37 x 10−6
Psychosis 1.83 × 10−7
ASD & ID 6.20 × 10−4
Ultra rare & rare (<0.01)
All neurodevelopmental 1.17 × 10−6
Psychosis 1.83 × 10−7
ASD & ID 6.06 x 10−6
SECOND DISCOVERY STUDY (838)
All functional
All (0.0–0.50) Schizophrenia 1.26 × 10−25
Utra rare & Rare (<0.01) Schizophrenia 3.55 × 10−7
LoF and missense
All (0.0–0.50) Schizophrenia 4.39 × 10−15
Utra rare & Rare (<0.01) Schizophrenia 0.138
Regulatory
All (0.0–0.50) Schizophrenia 7.37 × 10−22
Utra rare & Rare (<0.01) Schizophrenia 2.10 × 10−14
Table 2. Enrichment of variants within GRIK and NETO genes associated with neurodevelopmental disorders. 
LoF, missense and regulatory variants were analyzed by study phase and grouped by allele frequency and 
diagnosis. SKAT-O p values indicate a significant enrichment of risk and protective variants in affected 
individuals. Abbreviations ASD, Autism spectrum disorder; ID, intellectual disability.
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GluK4 L825W reduced glutamate potency of peak current generation for GluK2/GluK4 receptors by 42.6 
-fold (p = 0.0001, n = 10–18). Similarly, the GluK4 Y555N mutant decreased glutamate potency for GluK2/GluK4 
receptor peak currents by 15 -fold (p = 0.0001, n = 9–13). The GluK2 K525E LBD variant was not functional by 
itself but when co-expressed with GluK2, glutamate potency of GluK2 homomers was decreased by 4.5-fold 
(p < 0.05, n = 15–17) (Fig. 3a, b). These results imply decreased KAR channel activity.
The rate of current decay of GluK2/GluK4 L825W and GluK2/GluK4 Y555N heteromers was found to be 
2.3-fold slower (p = 0.047 and p = 0.002 respectively) than for GluK2/GluK4 wild type receptors upon applica-
tion of 0.1 mM glutamate (Fig. 3, Supplementary Table S20). This would suggest that both GluK4 mutations may 
result in mildly increased function through the channels potentially remaining open for a prolonged time. GluK2 
K525E did not significantly affect the rate of current decay. Taken together, our observations support that there is 
likely an overall decreased function in all mutants.
Discussion
Our findings from an integrated analysis of ~4,580 genomes investigated in two discovery phases, supports the 
hypothesis that LoF and damaging variants within KAR subunit and NETO genes are enriched in individuals 
with schizophrenia, autism and ID. Our observations of a specific candidate gene set are congruent with recent 
Figure 3. Altered channel properties of GluK2 and GluK4 mutants. (A) Top: Glutamate concentration-
response curves for wild type GluK2 and GluK2/GluK4 receptors and the mutated GluK2/GluK2 K525E, 
GluK2/GluK4 Y555N and GluK2/GluK4 L825W subunit combinations. Points are mean % of maximum 
peak response ± SEM and curves are fits of the Hill equation. Bottom: Comparisons of pEC50 for wild type 
and mutated GluK2 K525E, GluK4 Y555N, GluK4 L825W KARs. (B) Top: Two microelectrode voltage clamp 
(TEVC) traces for wild type and mutant GluK2 K525E, GluK4 Y555N, GluK4 L825W KARs in response to a 
10-s application (bar) of 1 mM glutamate (for wild type and mutated GluK2 receptors) or 0.1 mM glutamate 
(for wild type and mutated GluK2/GluK4 receptors) at −80 mV. The responses have been scaled such that 
the peak responses are equal to aid comparison of the current decay kinetics, hence there are no vertical 
scale bars. Bottom: Comparisons of current decay τ1 values for wild type and mutated GluK2 K525E, GluK4 
Y555N, GluK4 L825W KARs. Statistically significant differences are indicated by *(p < 0.05), **(p < 0.01) or 
****(p < 0.0001). Abbreviations: Glu, glutamate; hGluK2, human GluK2; KA, kainic acid, pEC50: negative 
logarithm of the EC50 value.
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large scale whole genome and exome studies of individuals with schizophrenia and schizophrenia with ID which 
report an increased burden of ultra-rare coding and common variants in genes characterised as missense and 
LoF variant depleted genes9,48. Likewise, our findings provide further support that, in addition to rare de novo 
variation as a strong causative factor for autism5,49, inherited LoF and damaging mutations can confer risk for 
autism and ID. We also confirm evidence that Scz, ASD and ID phenotypes share genetic predisposing factors 
and neuropathology50–52, and that variants with a spectrum of allele frequencies and effect size within GRIK and 
NETO genes contribute to these phenotypes.
We identified LoF and damaging missense variants across key protein domains of KAR subunits involved in 
specific functions. The majority of the significantly associated replicated alleles were found to be protective, e.g. 
GRIK3 S310A and are novel targets for future genetic studies. Our electrophysiological findings supported the 
idea that both LBD and TMD mutants altered channel gating behavior. However, variants may also impact upon 
KAR function by a number of alternative means. For instance, disruption of KAR and NETO interaction may 
affect the synaptic localisation of KARs53,54. Similarly, KAR CTD alterations could inhibit N-cadherin interaction 
and thereby influence synaptic compartmentalization and recruitment of KARs to the membrane55 and mutations 
disrupting C terminal PDZ ligand binding might influence secretory pathway processes, feedback systems and 
neuronal activity20. These synaptic-population and subcellular specific processes highlight the importance of KAR 
subunit availability and how variants, whether coding or acting through epigenetic mechanisms, could affect the 
KAR spatio-temporal patterns which may cause downstream alterations in the glutamate neurotransmission.
As with many NGS studies, a limitation of this study was that genomic coverage was dependent on read depth 
and quality of sequencing. Several regulatory UTR variants had to be excluded as they were not consistently called 
across cohorts and hence our results may have missed important regulatory KAR and NETOs alleles contribut-
ing to disease risk. For instance, we excluded an indel within the 3′UTR of GRIK4 which we previously reported 
confers protection against developing bipolar disorder through altering GluK4 RNA and protein abundance36,37. 
Furthermore, intronic variants which were not assessed within GRIK4 and GRIK3 have also shown significantly 
association with response to antidepressant and antipsychotic medication42,56–58.
Case-control GWAS studies of individuals with schizophrenia have recently indicated common alleles within 
transcripts of the C4 genes, which encodes a complement component 4 protein, and SNAP25, a vesicle fusion 
protein, contribute to risk of disease59,60. Both SNAP25 and members of a second complement cascade protein 
family (C1ql2 and C1ql3) are located at postsynaptic sites and bind to KAR subunits and thereby regulate KAR 
ion channel behaviour61,62. Further exploration of this emerging genetic risk pathway may aid in the development 
of new drugs to target neurodevelopmental conditions. Based on our findings, and with the need for translation 
from genetic risk factors to clear biomarkers of treatment response and disease prognosis, future studies using 
large population cohorts with collated phenotypic, genomic, medical and medication data (e.g. the UK biobank 
and USA ‘All of Us research program’) should involve the detailed characterisation of KAR and NETO risk alleles.
Methods and Materials
Individuals with a clinical diagnosis of neurodevelopmental disorders were exome sequenced as part of the neu-
rodevelopmental collections in the UK10K sequencing project (further details are provided in Supplementary 
Table S1). Ethical approval for genomic research and informed consent from all participants and/or their legal 
guardians was obtained previously by the UK10K consortium committee. The UK10K project was conducted in 
compliance with the Declaration of Helsinki statement of ethical principles. Access to the sequencing datasets 
was granted to Dr Knight under the UK10K Project access agreement ID5574. All individuals sequenced were of 
European ancestry.
In a first discovery phase, we examined approximately 846 individuals with schizophrenia or psychosis, 
550 individuals with ASD, 124 individuals with intellectual disability, and individuals with a dual diagnosis of 
either ASD comorbid with ID (77) or psychosis comorbid with ID (175) (Fig. 1). The numbers assessed vary 
owing to exclusion of poor sequencing data within different KAR/NETO genes. In a second discovery phase, 
two additional schizophrenia cohorts, (the NEURO UKSCZ N = 553; and NEURO FSZNK N = 285) were 
investigated. Population controls came from the population control arms of the UK10K project (TwinsUK10K, 
Obesity UK10K; N = 2,095). In a follow-up phase of the study we attempted to replicate allelic associations by 
first comparing MAFs of variants identified in the case discovery cohorts with MAFs reported for the ExAC gen-
eral population (N = 45,376). Subsequently, we compared alleles of interest in the psychiatric (N = 15,328) and 
non-psychiatric (N = 45,376) arms of the ExAC cohort.
Variant call files (VCF) were obtained from the European Genome-phenome Archive. VCF files for the 
non-psychiatric arm of ExAC was available from the ExAC website. The Genotype-Tissue Expression Project was 
used to identify primary transcripts expressed in brain and both brain-expressed and canonical transcripts were 
examined (Supplementary Table S2). A minimum of 12x read depth was accepted as a quality control. Functional 
annotation of coding variants was performed using snpEff, snpSift and dbNSFP. Variants were classified as: 
LoF variants (stop-gained, frameshift and splice-disrupting variants); missense; and regulatory (synonymous, 
non-damaging splicing site variants within 10 bp surrounding the exon and 3′UTR or 5′UTR variants). LoF anno-
tation was conducted using the LoF Transcript Effect Estimator (LOFTEE, version 0.2). Mutation Taster, Panther 
DB, Align GVGD and PolyPhen2 were used to predict whether missense mutations were damaging. Splicing 
effects were assessed using the Human Splicing Finder (HSF 3.0). Minor allele frequencies (MAFs) were calcu-
lated for variants identified in the discovery phases and compared with MAFs derived from general population 
databases, e.g. GnoMAD. Variants were classified as common (MAF > 0.05), low frequency (MAF = 0.05–0.01), 
rare (MAF = 0.01–0.001) and ultra-rare (MAF = 0.001–0.0001).
Single allele association analysis was performed using either the Fisher’s exact test or the chi square tests 
and were two tailed. P-values were adjusted for correction using the Holm-Bonferroni method and significance 
was set at two levels; a genome wide level (p < 5 × 10−8) and a less conservative nominal level (p < 1 × 10−6). 
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Odds Ratios (ORs) and confidence interval values were calculated using R software (v.3.4.1). Kernel methods 
SKAT and SKAT-O were implemented to identify genes carrying a significant burden of common, rare, and rare 
damaging variants63. Imputation of missing wild-type genotypes was conducted by using IMPUTE2 software64. 
Structural templates used for in silico protein modelling were acquired either from the Research Collaboratory 
for Structural Bioinformatics (RCSB) Protein Data Bank or generated from Uniprot amino acid sequences using 
RaptorX software65- further details are provided in Supplementary Table S3. In silico mutagenesis was performed 
using the mutagenesis function of Pymol (PyMOL Version 2.0, Schrödinger, LLC) and predicted hydrogen bonds 
within 8 A were examined in wild type and mutated structures. Free energy calculations (ΔG) were performed 
using FoldX v3.066. The Adaptive Poisson-Boltzmann Solver (APBS) software package was used to study surface 
potential changes in the electrostatic surface potential in mutant proteins67.
Wild-type and mutant KARs (GluK2 K525E, GluK4 Y555N, and GluK4 L825W) were expressed in Xenopus 
oocytes using methods described previously68. Xenopus oocytes were supplied as ovarian lobes by the European 
Xenopus Resource Centre, University of Portsmouth, UK. Animal care and treatment were conducted in compli-
ance with national and international laws and policies. The electrophysiology research protocol was performed 
in accordance with the University of Nottingham institutional guidelines and regulations. Human cDNA clones 
for GluK2 and GluK4 were obtained from GenScript (USA). Mutations were introduced into constructs using 
the QuikChange II Mutagenesis kit (Agilent Technologies) and cRNA generated using a mMessage mMachine 
kit (Invitrogen). Oocytes were injected with 50.6 nL cRNA (250–300 ng/μL) and incubated in GTP solution. 
Oocytes were perfused with frog Ringer solution at 10 mL/min and two-electrode voltage-clamped at −80 mV 
(Geneclamp 500, Axon Instruments). Glutamate was perfused at a flow rate of 10 mL/min at concentrations rang-
ing between 10−9 M and 10−3 M for 10 s. Peak current amplitudes were normalised and plotted against glutamate 
concentration to determine EC50. Current decay time constants (τ) were estimated over the 10-s glutamate appli-
cation by fitting exponential equations. Experiments were performed in multiple cells (n ≥ 5).
Data availability
The datasets generated during and/or analysed during the current study are not publicly available due access being 
granted to Dr Knight under the UK10K Project access agreement ID5574 but further information concerning 
identified variants is available from the corresponding author on reasonable request.
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